目的 探讨苏合香丸治疗新冠病毒感染后心动过速患者的有效性和安全性。方法 选择2023年2月—2023年3月解放军海军第971医院、常州市第二人民医院、徐州市第一人民医院、河南省人民医院、河南省胸科医院等8家医院收治的138例新型冠状病毒感染后心动过速患者，随机分为对照组和试验组，试验组87例，对照组51例。对照组使用倍他乐克治疗，1次/d，起始剂量23.75 mg，根据患者心率情况适时调整；试验组口服苏合香丸，1丸/次，2次/d。两组患者连续治疗7 d。观察两组患者的临床疗效，比较两组患者治疗前后心率和心功能指标、RR间期、血氧饱和度和不良反应情况。结果 治疗后试验组总有效率98.85%，对照组总有效率90.20%，两组比较差异具有统计学意义（P＜0.05）。治疗后两组患者的心率均有下降，与治疗前相比具有统计学差异（P＜0.05），试验组治疗后第7天时心率下降优于对照组（P＜0.05）。两组在治疗后第7天时左心室射血分数（left ventricular ejection fraction，LVEF）显著高于治疗前（P＜0.05），且试验组与对照组相比具有统计学差异（P＜0.05）；试验组左心室舒张末期内径（left ventricular end diastolic dimension，LVEDD）和左心室收缩末期内径（left ventricular end-systolic diameter，LVESD）从治疗第3天开始显著低于治疗前（P＜0.05），与对照组相比无统计学差异（P＞0.05）。两组患者均在治疗后第3天最大RR间期达到正常值范围，且试验组显著优于对照组（P＜0.05）。试验组在治疗后第7天血氧饱和度与治疗前相比显著增加（P＜0.05），但两组间比较差异无统计学意义（P＞0.05）。用药期间两组不良事件总发生率无统计学差异（P＞0.05）。结论 苏合香丸对新冠感染后心动过速患者心率改善有一定的疗效，与化学药作用相当，并且能一定程度上保护心脏，改善心功能。

Objective To explore the clinical effect and safety of Suhexiang Pills (苏合香丸) in the treatment of patients with tachycardia after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Methods A total of 138 patients with tachycardia after SARS-CoV-2 infection admitted to eight hospitals such as 971st Hospital of the PLA Navy, Changzhou Second People’s Hospital, Xuzhou First People’s Hospital, Henan Provincial People’s Hospital, Henan Chest Hospital from February 2023 to March 2023 were randomly divided into control group and treatment group, with 87 patients in the treatment group and 51 in the control group. Patients in the control group were po administered with betaloc, once a day, and the initial dose was 23.75 mg, adjusted in time according to the patient’s heart rate. Patients in the treatment group were po administered with Suhexiang Pills, 1 pill/time, twice daily. Patients in two groups were treated for 7 d. The clinical efficacy of the two groups was observed, and the heart rate and cardiac function indexes, RR interval, blood oxygen saturation and adverse reactions were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 98.85%, and the total effective rate of the control group was 90.20%, and the difference between the two groups was statistically significant (P < 0.05). After treatment, heart rates were significantly decreased in both groups (P < 0.05), and the heart rates of the treatment group were significantly better than those of the control group (P < 0.05) on the 7th day of treatment. After treatment, the level of left ventricular ejection fraction (LVEF) in both groups was significantly higher than that before treatment (P < 0.05), and there was statistical difference between the treatment group and the control group (P < 0.05). The levels of left ventricular end diastolic dimension (LVEDD) and left ventricular end-systolic diameter (LVESD) in the treatment group significantly decreased than that before treatment (P < 0.05), and there was no statistical difference compared with the control group (P > 0.05). After treatment, the maximum RR interval in both groups reached the normal range on the third day, and the treatment group was significantly better than the control group (P < 0.05). Blood oxygen saturation of the treatment group was significantly increased on the 7th day of treatment compared with before treatment (P < 0.05), but there was no statistical significance between the two groups (P > 0.05). There was no significant difference in the total incidence of adverse events between the two groups (P > 0.05). Conclusion Suhexiang Pills decrease heart rates in patients with tachycardia after SARS-CoV-2 infection, which was equivalent to the effect of western medicine, and can protect heart, improve heart function to a certain extent.

国家重点研发计划（2018YFC1705900）；国家中医药管理局2022年第五批新型冠状病毒感染肺炎中医药应急专项课（2022ZYLCY105-4）；上海中医药大学2022年度应对奥密克戎感染新型冠状病毒课题（2022Y-032022Y1-06）；国家中医药管理局项目：国家中医药多学科交叉创新团队项目（ZYYCXTD-D-202203）